Search

The authors have identified an error in thier manuscript and have incorrectly referred to the overall DISCERN score for SSc and RP as 2.21 and 1.99, respectively, in the abstract and discussion. The correct DISCERN quality scores are listed in Table 2.

Background:Immunoglobulin G4 related disease is a relatively rare multi-system disorder which can present with diverse manifestations including mass-lesions and, or, organ dysfunction. Although the orbits, salivary glands and sinuses are comparatively common sites of involvement there are few reports of isolated intracranial presentation. Case presentation:Although large vessel IgG4-RD vasculitis is an uncommon entity we report a case of a 84-year old male presenting with cerebellar ataxia. CT at presentation demonstrated bilateral low-density change in the middle cerebellar peduncles, which corelated to areas of elevated T2 signal demonstrating restricted diffusion on MRI. CT angiogram demonstrated marked thickening of the common carotid arteries and branches extending to the skull base. In addition, the vertebral arteries also demonstrated significant wall thickening and occlusive narrowing. Serum immunoglobulin IgG and IgA were elevated and in particular IgG immunoglobulin was extremely high.Conclusions:Bilateral symmetrical restricted diffusion in the middle cerebellar peduncles is a striking radiological feature and reported to occur with multiple aetiologies, we believe this is the first report to associate this with IgG4-RD and ataxia.

Raynaud's phenomenon is a common vasospastic condition which carries a significant burden of pain and hand-related disability ( Hughes and Herrick, 2016 ). The prevalence of Raynaud's phenomenon in the general population has been reported to be approximately 5% ( Garner et al, 2015 ). Raynaud's phenomenon can occur either as a primary (‘idiopathic’) phenomenon or secondary to a wide range of underlying medical conditions and drug causes. Therefore, hospital-based specialists are frequently involved in the care of patients with Raynaud's phenomenon and need to be aware of associated conditions and prescribed medications for Raynaud's phenomenon. In particular, Raynaud's phenomenon is often the earliest manifestation of an underlying autoimmune connective tissue disease (e.g. systemic sclerosis). A comprehensive clinical assessment is required including performing targeted investigations (e.g. nailfold capillaroscopy and systemic sclerosis-associated autoantibodies). Patient education and lifestyle adaptations is first-line treatment for Raynaud's phenomenon. There is a wide range of pharmacological options including oral and intravenous drug therapies available to treat Raynaud's phenomenon. Surgical intervention is sometimes required for refractory Raynaud's phenomenon and tissue ischaemia. This review describes the clinical manifestations of Raynaud's phenomenon including potential secondary causes and presents an approach to assessment and management.